Several other research analysts have also issued reports on the stock. Northland Securities reissued a buy rating on shares of Motif Bio in a research note on Monday, June 11th. Northland Capital Partners reissued a buy rating on shares of Motif Bio in a research note on Monday, June 11th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Motif Bio has an average rating of Buy and an average price target of GBX 109.40 ($1.41).
Shares of LON MTFB opened at GBX 33.50 ($0.43) on Tuesday. Motif Bio has a 12-month low of GBX 23.50 ($0.30) and a 12-month high of GBX 51.75 ($0.67).
About Motif Bio
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
Read More: Understanding Analyst Recommendations
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.